

***imi-rhapsody.eu***


*This project receives funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 115881.*

*This Joint Undertaking receives support from the European Union's Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA).*

*IMI2 is the world biggest public private partnership in life science.*

*Participants from Switzerland receive funding from the Swiss State Secretariat for Education, Research and Innovation (SERI) under contract number 16.0097.*

***Assessing risk and progression of pre-diabetes and type 2 diabetes to enable disease modification.***



RHAPSODY is a unique collaboration of over 100 researchers from academic, clinical and pharmaceutical research institutions. This project studies the progression of pre-diabetes to type 2 diabetes, the most frequent form of diabetes as well as the rate and impact of diabetes deterioration.

Diabetes is a pandemic disease, which currently affects 420 million people worldwide. Type 2 diabetes is characterised by an increase in blood glucose (sugar) levels, since the body is not able to effectively use the glucose as an energy source. Unfortunately, the effectiveness of current therapies varies considerably between individuals. Tailoring medical therapies to the patient's biological characteristics may help optimize disease prevention or treatment, thereby improving overall prognosis and reducing costs and side effects.

RHAPSODY brings together leading experts and resources in the field of type 2 diabetes, in particular unique collections of genetic, biochemical and clinical data as well as expertise in regulatory approval, health economics and patient engagement. Combining new and existing data, RHAPSODY will study the diversity of mechanisms leading to diabetes and its deterioration and identify novel biomarkers (measurable indicators of a biological state or condition) to stratify patients, ultimately leading to precision therapy and prevention of diabetes.

*imi-rhapsody.eu*  
*info@imi-rhapsody.eu*  
**0041 21 694 04 12**



## Our Consortium

Université de Lausanne Switzerland  
Lunds Universitet Sweden  
Technische Universität Dresden Germany  
Università di Pisa Italy  
Université Paris Diderot – Paris 7 France  
INSERM France  
Université Libre de Bruxelles Belgium  
Institut Suisse de Bioinformatique Switzerland  
University of Oxford United Kingdom  
CNRS France  
University of Eastern Finland Finland  
University of Dundee United Kingdom  
Imperial College London United Kingdom  
Eberhard Karls Universität Tübingen Germany  
Kobenhavns Universitet Denmark

### Academia

A.O.U. Città della Salute e della Scienza di Torino Italy  
UMCG – Groningen The Netherlands  
CHRU Lille France  
LUMC – Leiden The Netherlands  
VUmc – Amsterdam The Netherlands

### University hospitals

### Pharmaceutical Industries (EFPIA)

Institut de Recherches Servier France  
Janssen Pharmaceutica NV Belgium  
Novo Nordisk A/S Denmark  
Sanofi-Aventis Deutschland GMBH Germany

### Small and Medium-sized Enterprises

SCIPROM Sàrl Switzerland  
Lipotype GmbH Germany